Literature DB >> 27805919

FDG-Avid Intrathecal Inflammation Following Administration of Intrathecal Methotrexate.

Molly P Hogan1, Joseph Osborne, Gary A Ulaner.   

Abstract

Intrathecal methotrexate is a standard option for central nervous system-directed therapy in patients with stage III and IV diffuse large B-cell lymphoma. We present a case of a 50-year-old man with stage IV diffuse large B-cell lymphoma with widespread lymphomatous involvement including the central nervous system, who received 7 doses of intrathecal methotrexate via Ommaya catheter. Posttherapy F-FDG-PET/CT imaging demonstrated diffuse, intense intrathecal FDG avidity, without correlative findings on MR spinal imaging. FDG avidity resolved on follow-up. These PET/CT findings are most consistent with methotrexate-induced thecal inflammation, which needs to be distinguished from intrathecal malignancy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27805919      PMCID: PMC5583704          DOI: 10.1097/RLU.0000000000001440

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  9 in total

Review 1.  Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.

Authors:  Abhimanyu Ghose; Ria Kundu; Tahir Latif
Journal:  Crit Rev Oncol Hematol       Date:  2014-03-12       Impact factor: 6.312

2.  Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.

Authors:  Jeremy S Abramson; Matthew Hellmann; Jeffrey A Barnes; Peter Hammerman; Christiana Toomey; Tak Takvorian; Alona Muzikansky; Ephraim P Hochberg
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

3.  Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Authors:  Deepa Bhojwani; Noah D Sabin; Deqing Pei; Jun J Yang; Raja B Khan; John C Panetta; Kevin R Krull; Hiroto Inaba; Jeffrey E Rubnitz; Monika L Metzger; Scott C Howard; Raul C Ribeiro; Cheng Cheng; Wilburn E Reddick; Sima Jeha; John T Sandlund; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

Review 4.  Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.

Authors:  Hany R Guirguis; Matthew C Cheung; Mervat Mahrous; Eugenia Piliotis; Neil Berinstein; Kevin R Imrie; Liying Zhang; Rena Buckstein
Journal:  Br J Haematol       Date:  2012-07-31       Impact factor: 6.998

Review 5.  Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities.

Authors:  Yok-Lam Kwong; Dominic Y M Yeung; Joyce C W Chan
Journal:  Ann Hematol       Date:  2008-12-03       Impact factor: 3.673

6.  Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type.

Authors:  R Perez-Soler; T L Smith; F Cabanillas
Journal:  Cancer       Date:  1986-03-01       Impact factor: 6.860

7.  Imaging of spinal metastatic disease.

Authors:  Lubdha M Shah; Karen L Salzman
Journal:  Int J Surg Oncol       Date:  2011-11-03

8.  Methotrexate myelopathy after intrathecal chemotherapy: a case report.

Authors:  Ken-ya Murata; Ayaka Maeba; Mika Yamanegi; Ichiro Nakanishi; Hidefumi Ito
Journal:  J Med Case Rep       Date:  2015-06-09

9.  A case of the cauda equina syndrome associated with the intrathecal chemotherapy in a patient with primary central nervous system lymphoma.

Authors:  Seunglee Park; Jung-Il Kang; Hyun Bang; Bo-Ram Kim; Jongmin Lee
Journal:  Ann Rehabil Med       Date:  2013-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.